Focus Stocks
Allergan Broke Resistance
Published on Friday, 27 January 2012 06:28 Written by Danny Miller
New York, January 27th (TradersHuddle.com) - Shares of Allergan Inc. ( NYSE:AGN) closed the trading session at $88.97 just above calculated resistance at $88.81 effectively breaking out, grabbing the attention of momentum traders, which could eventually push the stock to different trading range
Allergan, Inc. ( NYSE:AGN) is a multi-specialty health care company that develops and commercializes pharmaceuticals, biologics and medical devices. The company develops products for the ophthalmic, neurological, medical aesthetics, breast aesthetics, obesity intervention, urological and other specialty markets in countries around the world.
Allergan's stock was trading in a well defined range with support at $78.42 and resistance at $88.81, given that this range was broken traders will be closely monitoring the stock
Related Articles
- Is Allergan Close to Support?
- Allergan Is Dipping Below Support
- Trading Idea: Momentum Building in Allergan
- Allergan Reports First Quarter 2012 Operating Results
- Allergan Is Close to the 50 Day Moving Average
- BOTOX® Cosmetic (onabotulinumtoxinA) Celebrates 10-Year Anniversary of U.S. Food and Drug Administration Approval
- Is Allergan Closing in to Resistance?
- Allergan Is Near its 50 Day Moving Average
- Allergan Announces Quarterly Conference Call
- Allergan Announces Positive Top-Line Results from Phase III BOTOX® Overactive Bladder Program
Related Partner Headlines
- Allergan Stock To Go Ex-dividend Tomorrow (AGN) - TheStreet.com
- Ex-Dividend Stocks: Thomson Reuters, Infosys - TheStreet.com
- Allergan Inc. (AGN): Today's Featured Drugs Winner - TheStreet.com
- Allergan Stock Hits New 52-Week High (AGN) - TheStreet.com
- Signs Point to MAP Pharma Drug Rejection - TheStreet.com
- Allergan Stock Hits New 52-Week High (AGN) - TheStreet.com
- Allergan Stock Hits New 52-Week High (AGN) - TheStreet.com
- Allergan Stock To Go Ex-dividend Tomorrow (AGN) - TheStreet.com
- 9 Ex-Dividend Stocks With Buy Ratings - TheStreet.com
- UPDATE: Morgan Stanley Raises Allergan's PT - Benzinga
TradersHuddle Search
| Sponsored By: |
|
Stock Search: |
|
Site Search: Loading
|
Recent Trading Ideas
Latest Partner Headlines
-
Japan's Consumer Prices Increase In April - Benzinga -
JP Morgan Lowers Australian Economic Growth Estimates - Benzinga -
Stocks To Watch For May 25 - Benzinga -
Top 4 Stocks In The Specialty Eateries Industry With The Highest Cash - Benzinga -
Top 4 Small-Cap Stocks In The Security Software & Services Industry With The Highest ROE - Benzinga -
Top 4 Small-Cap Stocks In The Health Care Plans Industry With The Highest Revenue - Benzinga -
Top 4 Small-Cap Stocks In The Heavy Construction Industry With The Lowest PEG Ratio - Benzinga -
Earnings Scheduled For May 25 - Benzinga
Stock Market
Dow Jones
Company ID [INDEXDJX:.DJI] Last trade:12,529.75 Trade time:4:05PM EDT Value change:▲33.60 (0.27%)S&P 500
Company ID [INDEXSP:.INX] Last trade:1,320.68 Trade time:4:32PM EDT Value change:▲1.82 (0.14%)NASDAQ
Company ID [INDEXNASDAQ:.IXIC] Last trade:2,839.38 Trade time:5:16PM EDT Value change:▼10.74 (-0.38%)In The Wires
-
BPH Symptoms Can Be Improved with New Thermobalancing Therapy Without Potentially Harmful Drugs & Prostate Surgeries, Reveals Fine Treatment -
How to Survive a Catastrophe with Absolute Rights’ Help -
“Pinterest for Marketing from the Leading Gurus in Social Media,” Says Online Article -
“Top Fracking Stocks Making Oil the Latest Industry Set to Boom All Over Again,” Says Absolute Wealth -
Do First Thing First - EzPaycheck Software Simplifies Payroll Tasks for Transportation Companies -
Metal Sheet Laser Cutting Machine Newly Launched -
Explore Tibet Announces Day Trip to Yamdrok Lake -
Baxter’s Low Glucose PD Solutions Favorably Impacted Metabolic Measures Including Glycemic Control in Trials of Diabetics Undergoing Dialysis









